ArticleBMC cancer2016

A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.

Ruben T H M Larue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.